ClinicalTrials.gg
CompletedNCT02679755Updated Jul 27, 2022Results posted

Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR+, HER2- Advanced Breast Cancer

A Phase 4 interventional study of Palbociclib and Letrozole in Breast Cancer, sponsored by Pfizer. Completed at 34 sites in 2 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-07-27.

Sponsored by Pfizer · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
252
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 111 studies testing palbociclib in Breast Neoplasms — 19 open to participants now, 43 under way, 9 of them phase 3. palbociclib · Breast Neoplasms.

Enrollment
26th of 111
252 · median 100
Started
2016
with 14 others
Phase 4
5 of 111
2 open now
Registered
35th of 111
by date
Lead sponsor
10 of 111
Pfizer

Among the 111 studies testing palbociclib in Breast Neoplasms, this one is the 26th largest by enrollment, is one of 15 that started in 2016, is one of 5 in phase 4, and was the 35th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

19 of the 111 studies testing palbociclib in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 19 open studies →

About palbociclib

palbociclib: first FDA approval 2015 (IBRANCE), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 111 studies testing palbociclib in Breast Neoplasms, or all of them as a file.
02

Study summary

A study of palbociclib in combination with letrozole as treatment of post-menopausal women with hormone receptor-positive, her2-negative advanced breast cancer for whom letrozole therapy is deemed appropriate.

Read the detailed description

To provide access to palbociclib to post-menopausal patients with hormone receptor-positive [HR(+)], HER2-negative [HER2(-)] ABC who are deemed appropriate for letrozole therapy.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Hormone receptor positive advanced breast cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women (>=18 years of age) with proven diagnosis of advanced carcinoma of the breast (ER(+) and/or PgR(+) and (-)) who are appropriate for letrozole therapy (in the advanced/ disease setting).
  • (ECOG) performance status 0-2.
  • Adequate bone marrow, liver, and renal function.

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with any CDK inhibitor .
  • >480 msec; history of QT syndrome, Brugada syndrome or known history of QTc prolongation, or Torsade de Pointes.
  • High cardiovascular risk, including, but not limited to myocardial infarction, severe/unstable angina, severe cardiac dysrhythmias, and symptomatic pulmonary embolism in the past 6 months of enrollment.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Masking
None (open label)
Enrollment
252 participants (actual)

Study arms

  • Experimental
    Experimental arm

    Palbociclib plus Letrozole

    Drug: Palbociclib · Drug: Letrozole

Interventions

  • 125 mg/d capsules orally for 3 out of 4 weeks in repeated cycles

    Also known as: IBRANCE

  • 2.5 mg/d tablets orally on a continuous regimen

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (All Causalities)

    An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product; the event did not need to have a causal relationship with the treatment. All AEs reported after initiation of study drug treatment were considered as treatment emergent adverse events (TEAEs). AE severity was graded according to Common Terminology Criteria for AEs (CTCAE) version 4.03. Grade 1 AEs are mild AEs; Grade 2 AEs are moderate AEs; Grade 3 AEs are severe AEs, Grade 4 AEs are life-threatening consequences and Grade 5 AEs are deaths related to AEs. Each AE was counted once for the participant in the most severe severity. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

    Time frame: Baseline up to 28 days after last dose of study treatment, an average of 14 months

  2. Number of Participants With Treatment-Emergent Adverse Events by Severity (All Causalities)

    An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product; the event did not need to have a causal relationship with the treatment. All AEs reported after initiation of study drug treatment were considered as TEAE. AE severity was graded according to Common Terminology Criteria for AEs (CTCAE) version 4.03. Grade 1 AEs are mild AEs; Grade 2 AEs are moderate AEs; Grade 3 AEs are severe AEs, Grade 4 AEs are life-threatening consequences and Grade 5 AEs are deaths related to AEs. Each AE was counted once for the participant in the most severe severity.

    Time frame: Baseline up to 28 days after last dose of study treatment, an average of 14 months

  3. Number of Participants With Treatment-Emergent Adverse Events (Palbociclib-Related)

    An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product; the event did not need to have a causal relationship with the treatment. All AEs reported after initiation of study drug treatment were considered as TEAE. AE severity was graded according to Common Terminology Criteria for AEs (CTCAE) version 4.03. Grade 1 AEs are mild AEs; Grade 2 AEs are moderate AEs; Grade 3 AEs are severe AEs, Grade 4 AEs are life-threatening consequences and Grade 5 AEs are deaths related to AEs. Each AE was counted once for the participant in the most severe severity. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Palbociclib-related TEAEs were determined by the investigator.

    Time frame: Baseline up to 28 days after last dose of study treatment, an average of 14 months

  4. Number of Participants With Treatment-Emergent Adverse Events by Severity (Palbociclib-Related)

    An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product; the event did not need to have a causal relationship with the treatment. All AEs reported after initiation of study drug treatment were considered as TEAE. AE severity was graded according to Common Terminology Criteria for AEs (CTCAE) version 4.03. Grade 1 AEs are mild AEs; Grade 2 AEs are moderate AEs; Grade 3 AEs are severe AEs, Grade 4 AEs are life-threatening consequences and Grade 5 AEs are deaths related to AEs. Each AE was counted once for the participant in the most severe severity. Palbociclib-related TEAEs were determined by the investigator.

    Time frame: Baseline up to 28 days after last dose of study treatment, an average of 14 months

  5. Number of Participants With Serious Adverse Events (All Causalities and Palbociclib-Related)

    An SAE was any untoward medical occurrence at any dose that resulted in death; was life threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in congenital anomaly/birth defect. Palbociclib-related SAEs were determined by the investigator.

    Time frame: Baseline up to 28 days after last dose of study treatment, an average of 14 months

Secondary outcomes

  1. Percentage of Participants With Complete Response and Partial Response

    Tumor response assessments were evaluated as per local guidelines by investigators and were collected in the CRF. No response confirmation was applied.

    Time frame: Baseline and per routine clinical practice to time of last dose of study treatment, an average of 1 year

  2. The Objective Response Rate (ORR)

    The tumor response was based on the response reported by investigator per local practice. No response confirmation was applied. ORR was defined as the percentage of participants with complete response or partial response relative to all as-treated population.

    Time frame: Baseline and per routine clinical practice to time of last dose of study treatment, an average of 1 year

  3. EQ-5D Health Utility Index Score

    The EuroQol-5D (EQ-5D) (version 3L) consisted of 2 parts. The first part was a 5 item questionnaire designed to assess health status in terms of a single index value or utility score. It consisted of 5 descriptors of current health state (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). A respondent was asked to rate each state on a three level scale (1=no problem, 2=some problem, and 3=extreme problem) with higher levels indicating greater severity/impairment. The answers given to the 5 descriptors permit to find 243 unique health states which can be converted into a single EQ-5D index value by published algorithms. For the EQ-5D index, published weights are available that allow for the creation of a summary score ranging from -0.594 to 1, with low scores representing a higher level of dysfunction and 1 as perfect health.

    Time frame: The descriptive analysis was carried out on Day 1 of each cycle (cycle 1 to cycle 38), at end of treatment (EOT) and end of study (EOS), up to 3 years. Cycle 1 Day 1 is taken to be baseline.

  4. Change From Baseline in EQ-5D Health Utility Index Score

    The EuroQol-5D (EQ-5D) (version 3L) consisted of 2 parts. The first part was a 5 item questionnaire designed to assess health status in terms of a single index value or utility score. It consisted of 5 descriptors of current health state (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). A respondent was asked to rate each state on a three level scale (1=no problem, 2=some problem, and 3=extreme problem) with higher levels indicating greater severity/impairment. The answers given to the 5 descriptors permit to find 243 unique health states which can be converted into a single EQ-5D index value by published algorithms. For the EQ-5D index, published weights are available that allow for the creation of a summary score ranging from -0.594 to 1, with low scores representing a higher level of dysfunction and 1 as perfect health.

    Time frame: The descriptive analysis was carried out on Day 1 of each cycle (cycle 1 to cycle 38), at end of treatment (EOT) and end of study (EOS), up to 3 years. Cycle 1 Day 1 is taken to be baseline.

  5. EQ-VAS Score

    The EuroQol-5D (EQ-5D) (version 3L) consisted of 2 parts. The second part consisted of a visual analogue scale (the EuroQol-visual analogue scale \[EQ-VAS\]). The respondent's self-rated health was assessed on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state)

    Time frame: The descriptive analysis was carried out on Day 1 of each cycle (cycle 1 to cycle 38), at end of treatment (EOT) and end of study (EOS), up to 3 years. Cycle 1 Day 1 is taken to be baseline.

  6. Change From Baseline in EQ-VAS Score

    The EuroQol-5D (EQ-5D) (version 3L) consisted of 2 parts. The second part consisted of a visual analogue scale (the EuroQol-visual analogue scale \[EQ-VAS\]). The respondent's self-rated health was assessed on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state)

    Time frame: The descriptive analysis was carried out on Day 1 of each cycle (cycle 1 to cycle 38), at end of treatment (EOT) and end of study (EOS), up to 3 years. Cycle 1 Day 1 is taken to be baseline.

07

Results

Posted Oct 5, 2020

Participant flow

Participant flow — Overall Study
MilestonePalbociclib+Letrozole India CohortPalbociclib+Letrozole Australia Cohort
Started100152
Completed6647
Not completed34105
Withdrew: Death03
Withdrew: Global deterioration of health status18
Withdrew: Lost to follow-up10
Withdrew: Objective progression or relapse2483
Withdrew: Not defined02
Withdrew: Withdrawal by participant63
Withdrew: Adverse event14
Withdrew: Adverse events not related to study drug12

Outcome measures

PrimaryNumber of Participants With Treatment-Emergent Adverse Events (All Causalities)

An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product; the event did not need to have a causal relationship with the treatment. All AEs reported after initiation of study drug treatment were considered as treatment emergent adverse events (TEAEs). AE severity was graded according to Common Terminology Criteria for AEs (CTCAE) version 4.03. Grade 1 AEs are mild AEs; Grade 2 AEs are moderate AEs; Grade 3 AEs are severe AEs, Grade 4 AEs are life-threatening consequences and Grade 5 AEs are deaths related to AEs. Each AE was counted once for the participant in the most severe severity. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

Time frame:
Baseline up to 28 days after last dose of study treatment, an average of 14 months
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (All Causalities)
ParticipantsPalbociclib+Letrozole India CohortPalbociclib+Letrozole Australia CohortPalbociclib+LetrozoleTotal
Participants with adverse events92152244
Participants with serious adverse events184563
Participants with grade 3 or 4 adverse events69124193
Participants with grade 5 adverse events3710
Participants discontinued due to adverse events2911
PrimaryNumber of Participants With Treatment-Emergent Adverse Events by Severity (All Causalities)

An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product; the event did not need to have a causal relationship with the treatment. All AEs reported after initiation of study drug treatment were considered as TEAE. AE severity was graded according to Common Terminology Criteria for AEs (CTCAE) version 4.03. Grade 1 AEs are mild AEs; Grade 2 AEs are moderate AEs; Grade 3 AEs are severe AEs, Grade 4 AEs are life-threatening consequences and Grade 5 AEs are deaths related to AEs. Each AE was counted once for the participant in the most severe severity.

Time frame:
Baseline up to 28 days after last dose of study treatment, an average of 14 months
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events by Severity (All Causalities)
ParticipantsPalbociclib+Letrozole India CohortPalbociclib+Letrozole Australia CohortPalbociclib+Letrozole Total
Grade 171118
Grade 2161632
Grade 349105154
Grade 4171330
Grade 53710
PrimaryNumber of Participants With Treatment-Emergent Adverse Events (Palbociclib-Related)

An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product; the event did not need to have a causal relationship with the treatment. All AEs reported after initiation of study drug treatment were considered as TEAE. AE severity was graded according to Common Terminology Criteria for AEs (CTCAE) version 4.03. Grade 1 AEs are mild AEs; Grade 2 AEs are moderate AEs; Grade 3 AEs are severe AEs, Grade 4 AEs are life-threatening consequences and Grade 5 AEs are deaths related to AEs. Each AE was counted once for the participant in the most severe severity. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Palbociclib-related TEAEs were determined by the investigator.

Time frame:
Baseline up to 28 days after last dose of study treatment, an average of 14 months
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (Palbociclib-Related)
ParticipantsPalbociclib+Letrozole India CohortPalbociclib+Letrozole Australia CohortPalbociclib+Letrozole Total
Participants with adverse events80143223
Participants with serious adverse events81220
Participants with grade 3 or 4 adverse events64108172
Participants with grade 5 adverse events011
Participants discontinued due to adverse events145
PrimaryNumber of Participants With Treatment-Emergent Adverse Events by Severity (Palbociclib-Related)

An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product; the event did not need to have a causal relationship with the treatment. All AEs reported after initiation of study drug treatment were considered as TEAE. AE severity was graded according to Common Terminology Criteria for AEs (CTCAE) version 4.03. Grade 1 AEs are mild AEs; Grade 2 AEs are moderate AEs; Grade 3 AEs are severe AEs, Grade 4 AEs are life-threatening consequences and Grade 5 AEs are deaths related to AEs. Each AE was counted once for the participant in the most severe severity. Palbociclib-related TEAEs were determined by the investigator.

Time frame:
Baseline up to 28 days after last dose of study treatment, an average of 14 months
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events by Severity (Palbociclib-Related)
ParticipantsPalbociclib+Letrozole India CohortPalbociclib+Letrozole Australia CohortPalbociclib+Letrozole Total
Grade 162127
Grade 2101424
Grade 34993142
Grade 4151429
Grade 5011
PrimaryNumber of Participants With Serious Adverse Events (All Causalities and Palbociclib-Related)

An SAE was any untoward medical occurrence at any dose that resulted in death; was life threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in congenital anomaly/birth defect. Palbociclib-related SAEs were determined by the investigator.

Time frame:
Baseline up to 28 days after last dose of study treatment, an average of 14 months
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events (All Causalities and Palbociclib-Related)
ParticipantsPalbociclib+Letrozole India CohortPalbociclib+Letrozole Australia CohortPalbociclib+Letrozole Total
All-causality184563
Palciclib-Related81220
SecondaryPercentage of Participants With Complete Response and Partial Response

Tumor response assessments were evaluated as per local guidelines by investigators and were collected in the CRF. No response confirmation was applied.

Time frame:
Baseline and per routine clinical practice to time of last dose of study treatment, an average of 1 year
Reported as:
Number · Percentage of evaluable participants
Percentage of Participants With Complete Response and Partial Response
Percentage of evaluable participantsPalbociclib+Letrozole India CohortPalbociclib+Letrozole Australia CohortPalbociclib+Letrozole Total
Percentage of participants with complete response1.01.31.2
Percentage of participants with partial response28.011.818.3
SecondaryThe Objective Response Rate (ORR)

The tumor response was based on the response reported by investigator per local practice. No response confirmation was applied. ORR was defined as the percentage of participants with complete response or partial response relative to all as-treated population.

Time frame:
Baseline and per routine clinical practice to time of last dose of study treatment, an average of 1 year
Reported as:
Number · Percentage of evaluable participants
The Objective Response Rate (ORR)
Percentage of evaluable participantsPalbociclib+Letrozole India CohortPalbociclib+Letrozole Australia CohortPalbociclib+Letrozole Total
The Objective Response Rate (ORR)29.0 (20.4 to 38.9)13.2 (8.2 to 19.6)19.4 (14.7 to 24.9)
SecondaryEQ-5D Health Utility Index Score

The EuroQol-5D (EQ-5D) (version 3L) consisted of 2 parts. The first part was a 5 item questionnaire designed to assess health status in terms of a single index value or utility score. It consisted of 5 descriptors of current health state (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). A respondent was asked to rate each state on a three level scale (1=no problem, 2=some problem, and 3=extreme problem) with higher levels indicating greater severity/impairment. The answers given to the 5 descriptors permit to find 243 unique health states which can be converted into a single EQ-5D index value by published algorithms. For the EQ-5D index, published weights are available that allow for the creation of a summary score ranging from -0.594 to 1, with low scores representing a higher level of dysfunction and 1 as perfect health.

Time frame:
The descriptive analysis was carried out on Day 1 of each cycle (cycle 1 to cycle 38), at end of treatment (EOT) and end of study (EOS), up to 3 years. Cycle 1 Day 1 is taken to be baseline.
Reported as:
Mean · Scores on a scale
EQ-5D Health Utility Index Score
Scores on a scalePalbociclib+Letrozole India CohortPalbociclib+Letrozole Australia Cohort
Cycle 1 Day 1—0.786 ± 0.171
Cycle 2 Day 1—0.798 ± 0.187
Cycle 3 Day 1—0.798 ± 0.169
Cycle 4 Day 1—0.836 ± 0.172
Cycle 5 Day 1—0.838 ± 0.153
Cycle 6 Day 1—0.825 ± 0.185
Cycle 7 Day 1—0.818 ± 0.167
Cycle 8 Day 1—0.831 ± 0.169
Cycle 9 Day 1—0.845 ± 0.149
Cycle 10 Day 1—0.840 ± 0.162
Cycle 11 Day 1—0.820 ± 0.193
Cycle 12 Day 1—0.810 ± 0.188
Cycle 13 Day 1—0.839 ± 0.183
Cycle 14 Day 1—0.842 ± 0.159
Cycle 15 Day 1—0.840 ± 0.138
Cycle 16 Day 1—0.830 ± 0.182
Cycle 17 Day 1—0.837 ± 0.163
Cycle 18 Day 1—0.836 ± 0.182
Cycle 19 Day 1—0.848 ± 0.179
Cycle 20 Day 1—0.853 ± 0.143
Cycle 21 Day 1—0.868 ± 0.132
Cycle 22 Day 1—0.864 ± 0.132
Cycle 23 Day 1—0.846 ± 0.170
Cycle 24 Day 1—0.864 ± 0.135
Cycle 25 Day 1—0.861 ± 0.138
Cycle 26 Day 1—0.869 ± 0.143
Cycle 27 Day 1—0.884 ± 0.140
Cycle 28 Day 1—0.876 ± 0.152
Cycle 29 Day 1—0.852 ± 0.147
Cycle 30 Day 1—0.857 ± 0.160
Cycle 31 Day 1—0.784 ± 0.278
Cycle 32 Day 1—0.864 ± 0.163
Cycle 33 Day 1—0.870 ± 0.140
Cycle 34 Day 1—0.838 ± 0.160
Cycle 35 Day 1—0.905 ± 0.128
Cycle 36 Day 1—0.779 ± 0.294
Cycle 37 Day 1—0.854 ± 0.170
Cycle 38 Day 1—0.810 ± 0.269
End of Treatment (EOT)—0.698 ± 0.324
End of Study (EOS)—0.770 ± 0.247
SecondaryChange From Baseline in EQ-5D Health Utility Index Score

The EuroQol-5D (EQ-5D) (version 3L) consisted of 2 parts. The first part was a 5 item questionnaire designed to assess health status in terms of a single index value or utility score. It consisted of 5 descriptors of current health state (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). A respondent was asked to rate each state on a three level scale (1=no problem, 2=some problem, and 3=extreme problem) with higher levels indicating greater severity/impairment. The answers given to the 5 descriptors permit to find 243 unique health states which can be converted into a single EQ-5D index value by published algorithms. For the EQ-5D index, published weights are available that allow for the creation of a summary score ranging from -0.594 to 1, with low scores representing a higher level of dysfunction and 1 as perfect health.

Time frame:
The descriptive analysis was carried out on Day 1 of each cycle (cycle 1 to cycle 38), at end of treatment (EOT) and end of study (EOS), up to 3 years. Cycle 1 Day 1 is taken to be baseline.
Reported as:
Mean · Scores on a scale
Change From Baseline in EQ-5D Health Utility Index Score
Scores on a scalePalbociclib+Letrozole India CohortPalbociclib+Letrozole Australia Cohort
Baseline (Cycle 1 Day 1)—0.786 ± 0.171
Cycle 2 Day 1—0.013 ± 0.172
Cycle 3 Day 1—0.021 ± 0.156
Cycle 4 Day 1—0.052 ± 0.175
Cycle 5 Day 1—0.052 ± 0.181
Cycle 6 Day 1—0.037 ± 0.214
Cycle 7 Day 1—0.033 ± 0.173
Cycle 8 Day 1—0.050 ± 0.156
Cycle 9 Day 1—0.057 ± 0.165
Cycle 10 Day 1—0.049 ± 0.192
Cycle 11 Day 1—0.034 ± 0.225
Cycle 12 Day 1—0.029 ± 0.235
Cycle 13 Day 1—0.058 ± 0.203
Cycle 14 Day 1—0.058 ± 0.188
Cycle 15 Day 1—0.062 ± 0.184
Cycle 16 Day 1—0.051 ± 0.182
Cycle 17 Day 1—0.059 ± 0.165
Cycle 18 Day 1—0.060 ± 0.181
Cycle 19 Day 1—0.061 ± 0.179
Cycle 20 Day 1—0.069 ± 0.197
Cycle 21 Day 1—0.082 ± 0.169
Cycle 22 Day 1—0.076 ± 0.081
Cycle 23 Day 1—0.073 ± 0.193
Cycle 24 Day 1—0.085 ± 0.183
Cycle 25 Day 1—0.083 ± 0.192
Cycle 26 Day 1—0.052 ± 0.140
Cycle 27 Day 1—0.063 ± 0.129
Cycle 28 Day 1—0.071 ± 0.153
Cycle 29 Day 1—0.056 ± 0.126
Cycle 30 Day 1—0.055 ± 0.122
Cycle 31 Day 1—-0.013 ± 0.243
Cycle 32 Day 1—0.049 ± 0.099
Cycle 33 Day 1—0.060 ± 0.098
Cycle 34 Day 1—0.026 ± 0.123
Cycle 35 Day 1—0.092 ± 0.134
Cycle 36 Day 1—-0.036 ± 0.240
Cycle 37 Day 1—0.011 ± 0.107
Cycle 38 Day 1—-0.012 ± 0.232
End of Treatment (EOT)—-0.147 ± 0.239
End of Study (EOT)—-0.022 ± 0.228
SecondaryEQ-VAS Score

The EuroQol-5D (EQ-5D) (version 3L) consisted of 2 parts. The second part consisted of a visual analogue scale (the EuroQol-visual analogue scale \[EQ-VAS\]). The respondent's self-rated health was assessed on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state)

Time frame:
The descriptive analysis was carried out on Day 1 of each cycle (cycle 1 to cycle 38), at end of treatment (EOT) and end of study (EOS), up to 3 years. Cycle 1 Day 1 is taken to be baseline.
Reported as:
Mean · Scores on a scale
EQ-VAS Score
Scores on a scalePalbociclib+Letrozole India CohortPalbociclib+Letrozole Australia Cohort
Cycle 1 Day 1—76.9 ± 16.00
Cycle 2 Day 1—77.3 ± 15.29
Cycle 3 Day 1—77.4 ± 15.52
Cycle 4 Day 1—80.3 ± 14.17
Cycle 5 Day 1—80.4 ± 14.66
Cycle 6 Day 1—79.8 ± 15.77
Cycle 7 Day 1—79.7 ± 14.81
Cycle 8 Day 1—80.1 ± 13.75
Cycle 9 Day 1—80.9 ± 14.54
Cycle 10 Day 1—81.2 ± 14.75
Cycle 11 Day 1—81.0 ± 14.60
Cycle 12 Day 1—81.3 ± 13.99
Cycle 13 Day 1—80.4 ± 14.37
Cycle 14 Day 1—80.9 ± 13.72
Cycle 15 Day 1—82.1 ± 12.24
Cycle 16 Day 1—82.9 ± 12.93
Cycle 17 Day 1—83.1 ± 12.89
Cycle 18 Day 1—83.1 ± 12.31
Cycle 19 Day 1—83.7 ± 12.75
Cycle 20 Day 1—84.5 ± 12.10
Cycle 21 Day 1—85.3 ± 12.03
Cycle 22 Day 1—85.5 ± 11.77
Cycle 23 Day 1—84.1 ± 14.30
Cycle 24 Day 1—85.6 ± 12.78
Cycle 25 Day 1—84.9 ± 12.89
Cycle 26 Day 1—87.6 ± 11.08
Cycle 27 Day 1—88.1 ± 9.88
Cycle 28 Day 1—87.5 ± 9.32
Cycle 29 Day 1—88.5 ± 9.98
Cycle 30 Day 1—91.5 ± 6.97
Cycle 31 Day 1—88.1 ± 12.26
Cycle 32 Day 1—91.0 ± 8.06
Cycle 33 Day 1—88.6 ± 10.61
Cycle 34 Day 1—91.0 ± 8.06
Cycle 35 Day 1—90.0 ± 11
Cycle 36 Day 1—87.5 ± 14.84
Cycle 37 Day 1—91.5 ± 7.42
Cycle 38 Day 1—91.5 ± 0.71
End of Treatment (EOT)—73.6 ± 23.88
End of Study (EOS)—77.3 ± 18.99
SecondaryChange From Baseline in EQ-VAS Score

The EuroQol-5D (EQ-5D) (version 3L) consisted of 2 parts. The second part consisted of a visual analogue scale (the EuroQol-visual analogue scale \[EQ-VAS\]). The respondent's self-rated health was assessed on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state)

Time frame:
The descriptive analysis was carried out on Day 1 of each cycle (cycle 1 to cycle 38), at end of treatment (EOT) and end of study (EOS), up to 3 years. Cycle 1 Day 1 is taken to be baseline.
Reported as:
Mean · Scores on a scale
Change From Baseline in EQ-VAS Score
Scores on a scalePalbociclib+Letrozole India CohortPalbociclib+Letrozole Australia Cohort
Baseline (Cycle 1 Day 1)—76.9 ± 16.00
Cycle 2 Day 1—0.4 ± 13.28
Cycle 3 Day 1—0.3 ± 13.47
Cycle 4 Day 1—2.9 ± 13.06
Cycle 5 Day 1—3.2 ± 14.70
Cycle 6 Day 1—2.3 ± 15.53
Cycle 7 Day 1—2.0 ± 15.79
Cycle 8 Day 1—2.4 ± 13.64
Cycle 9 Day 1—2.3 ± 12.54
Cycle 10 Day 1—2.4 ± 14.44
Cycle 11 Day 1—2.1 ± 13.72
Cycle 12 Day 1—2.9 ± 13.76
Cycle 13 Day 1—2.1 ± 13.84
Cycle 14 Day 1—2.3 ± 14.00
Cycle 15 Day 1—3.5 ± 12.12
Cycle 16 Day 1—3.7 ± 13.82
Cycle 17 Day 1—3.9 ± 12.77
Cycle 18 Day 1—4.5 ± 11.86
Cycle 19 Day 1—4.6 ± 11.69
Cycle 20 Day 1—5.5 ± 12.58
Cycle 21 Day 1—6.0 ± 11.77
Cycle 22 Day 1—5.0 ± 9.71
Cycle 23 Day 1—4.4 ± 13.20
Cycle 24 Day 1—4.6 ± 11.93
Cycle 25 Day 1—4.3 ± 10.71
Cycle 26 Day 1—4.4 ± 8.63
Cycle 27 Day 1—5.6 ± 6.26
Cycle 28 Day 1—5.5 ± 8.24
Cycle 29 Day 1—5.9 ± 7.57
Cycle 30 Day 1—6.5 ± 7.88
Cycle 31 Day 1—4.3 ± 11.52
Cycle 32 Day 1—7.3 ± 10.59
Cycle 33 Day 1—7.1 ± 12.75
Cycle 34 Day 1—7.6 ± 6.68
Cycle 35 Day 1—6.6 ± 9.27
Cycle 36 Day 1—3.5 ± 8.22
Cycle 37 Day 1—10.3 ± 1.71
Cycle 38 Day 1—9.0 ± 4.24
End of Treatment (EOT)—-3.2 ± 22.24
End of Study (EOS)—0.4 ± 19.72

Adverse events

Collected over AEs (serious and non-serious) were recorded on the CRF from the time the participant had taken at least 1 dose of investigational product through and including 28 calendar days after the last administration of the study treatment, an average of 14 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Palbociclib+Letrozole India Cohort3/100 (3%)18/100 (18%)85/100 (85%)
Palbociclib+Letrozole Australia Cohort7/152 (4.6%)45/152 (29.6%)151/152 (99.3%)
Most frequent serious events
Showing 10 of 58
Most frequent serious events
EventPalbociclib+Letrozole India CohortPalbociclib+Letrozole Australia Cohort
AnaemiaBlood and lymphatic system disorders4/1000/152
Disease progressionGeneral disorders2/1006/152
DyspnoeaRespiratory, thoracic and mediastinal disorders0/1005/152
Febrile neutropeniaBlood and lymphatic system disorders3/1003/152
VomitingGastrointestinal disorders3/1000/152
Pathological fractureMusculoskeletal and connective tissue disorders3/1001/152
Lower respiratory tract infectionInfections and infestations2/1001/152
Urinary tract infectionInfections and infestations1/1003/152
Abdominal painGastrointestinal disorders0/1002/152
Abdominal pain upperGastrointestinal disorders0/1002/152
Most frequent other events
Showing 10 of 57
Most frequent other events
EventPalbociclib+Letrozole India CohortPalbociclib+Letrozole Australia Cohort
NeutropeniaBlood and lymphatic system disorders57/100110/152
FatigueGeneral disorders9/10099/152
NauseaGastrointestinal disorders3/10057/152
Upper respiratory tract infectionInfections and infestations5/10057/152
ArthralgiaMusculoskeletal and connective tissue disorders6/10052/152
DiarrhoeaGastrointestinal disorders7/10051/152
HeadacheNervous system disorders4/10047/152
Back painMusculoskeletal and connective tissue disorders9/10035/152
Hot flushVascular disorders0/10035/152
Mouth ulcerationGastrointestinal disorders3/10034/152

Baseline characteristics

The analysis population included all participants who received at least 1 dose of palbociclib treatment.

Age, Categorical
Age, Categorical(Participants)Palbociclib+Letrozole India CohortPalbociclib+Letrozole Australia CohortTotal
<=18 years000
Between 18 and 65 years71107178
>=65 years294574
Sex: Female, Male
Sex: Female, Male(Participants)Palbociclib+Letrozole India CohortPalbociclib+Letrozole Australia CohortTotal
Female100152252
Male000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Palbociclib+Letrozole India CohortPalbociclib+Letrozole Australia CohortTotal
American Indian or Alaska Native000
Asian10012112
Native Hawaiian or Other Pacific Islander000
Black or African American011
White0130130
More than one race000
Unknown or Not Reported099
08

Study locations

34 sites
  • Benjamin Carl Forster
    North Sydney, New South Wales 2060, Australia
  • Dr. Alexander Maxwell Menzies
    North Sydney, New South Wales 2060, Australia
  • HPS Pharmacies - North Sydney
    North Sydney, New South Wales 2060, Australia
  • Mater Hospital Sydney
    North Sydney, New South Wales 2060, Australia
  • Professor Frances Mary Boyle
    North Sydney, New South Wales 2060, Australia
  • Royal North Shore Hospital - Clinical Trials Pharmacy
    St Leonards, New South Wales 2065, Australia
  • Royal North Shore Hospital, Dept. of Medical Oncology
    St Leonards, New South Wales 2065, Australia
  • Icon Cancer Care Wesley
    Auchenflower, Queensland 4066, Australia
  • River City Pharmacy
    Auchenflower, Queensland 4066, Australia
  • Icon Cancer Care Chermside
    Chermside, Queensland 4032, Australia
  • Icon Cancer Care South Brisbane
    South Brisbane, Queensland 4101, Australia
  • Icon Cancer Care, Corporate Office
    South Brisbane, Queensland 4101, Australia
  • Icon Cancer Care Southport
    Southport, Queensland 4215, Australia
  • Flinders Medical Centre-Pharmacy Department
    Bedford Park, South Australia 5042, Australia
  • Flinders Medical Centre
    Bedford Park, South Australia 5042, Australia
  • Monash Health
    Clayton, Victoria 3168, Australia
  • Peter MacCallum Cancer Centre Pharmacy
    Melbourne, Victoria 3000, Australia
  • Peter MacCallum Cancer Centre
    Melbourne, Victoria 3000, Australia
  • Sunshine Hospital
    St Albans, Victoria 3021, Australia
  • Sunshine Hospital Pharmacy
    St. Albans, Victoria 3021, Australia
  • Fiona Stanley Hospital
    Murdoch, Western Australia 6150, Australia
  • Pharmacy Department
    Murdoch, Western Australia 6150, Australia
  • Rajiv Gandhi Cancer Institute And Research Centre
    New Delhi, Delhi 110 085, India
  • Dr. B.R.A Institute Rotary Cancer Hospital, All India Institue of Medical Sciences
    New Delhi, Delhi 110029, India
  • The Gujarat Cancer & Research Institute, M.P Shah Cancer Hospital
    Ahmedabad, Gujarat 380016, India
  • Manipal Hospital
    Bangalore, Karnataka 560017, India
  • HealthCare Global Enterprises Ltd.
    Bangalore, Karnataka 560027, India
  • Kasturba Hospital
    Manipal, Karnataka 576104, India
  • Tata Memorial Centre, Tata Memorial Hospital
    Mumbai, Maharashtra 400 012, India
  • Meditrina Institute Of Medical Sciences
    Nagpur, Maharashtra 440012, India
  • Shatabdi Hospital
    Nashik, Maharashtra 422005, India
  • Deenanath Mangeshkar Hospital and Research Center
    Pune, Maharashtra 411 004, India
  • Sahyadri Super Speciality Hospital
    Pune, Maharashtra 411004, India
  • Apollo Speciality Hospital
    Chennai, Tamilnadu 600 035, India
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2016 to primary completion in Jul 2019, 40 months.

Results were first posted in Oct 2020, 1 year 2 months after primary completion.

Of 130 phase 4 interventional studies under Breast Neoplasms, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 64. This study's 40 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2016
First posted
Feb 10, 2016
StartActual
Mar 9, 2016
Primary completionActual
Jul 25, 2019
CompletionActual
Jul 25, 2019
Results first posted
Oct 5, 2020
Last update
Jul 27, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02679755
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Feb 10, 2016
Start date
Mar 9, 2016
Primary completion
Jul 25, 2019
Completion
Jul 25, 2019
Results posted
Oct 5, 2020
Last update
Jul 27, 2022

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Palbociclib · Letrozole

Start the discussion